The study by Grieshaber and colleagues, “Platelet-activating protamine-heparin-antibodies lead to higher protamine demand in patients undergoing cardiac surgery,” in this issue of the Journal,¹ is a prospective study that joins other recent publications aiming to answer an intriguing clinical question: Do antibodies against heparin-protamine complexes have a significant clinical influence?